Drug Profile
RX 0301
Alternative Names: HC-0301; RX-0301; WGI-0301Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Rexahn Pharmaceuticals
- Developer Rexahn Pharmaceuticals; Zhejiang Haichang Biotechnology
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Discontinued Ovarian cancer; Pancreatic cancer; Renal cell carcinoma
Most Recent Events
- 14 Apr 2023 Pharmacodynamics and adverse events data from preclinical studies in Liver cancer were presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Renal cell carcinoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 01 Aug 2022 Phase-I clinical trials in Solid tumours(Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT05267899)